When deciding which postmenopausal women under 65 to screen, the USPSTF recommended that clinicians first take stock of risk ...

In a final recommendation statement, the U.S. Preventive Services Task Force said that all women aged 65 years and older ...

Researchers at Hospital for Special Surgery (HSS) have pinpointed a cellular target that could enhance the way osteoporosis ...

Menopause is a huge mental, emotional and physical change. Here's what you need to know about this stage of life, including ...

All women 65 and older should continue to be screened for osteoporosis, the nation’s leading preventive health panel ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in ...

The U.S Preventive Services Task Force (USPSTF) recommends osteoporosis screening to prevent osteoporotic fractures for all ...

Raloxifene is FDA approved for the prevention and treatment of postmenopausal osteoporosis and for the prevention of invasive breast cancer in postmenopausal women at high risk for breast cancer.

All treatments for 2 yr BMD improved more ... group had reduction in UcOC without change in OC 54 94 postmenopausal women with osteoporosis (84 controls, 10 treated) Menaquinone 45 mg/day ...

“Osteoporosis is a condition where the bones become weaker and break more easily, even after a minor bump or fall,” explains ...

Women who are aged 65 and older should continue to receive osteoporosis screenings, according to an advisory panel’s updated ...